Although these findings do not identify a target that is specific for TNBC over other breast cancer subtypes, they do confirm the expression of high levels of HIF-1α at the transcriptional and protein levels in a variety of breast tumors, which may benefit from such targeted therapy, especially in the setting of clinically aggressive and drug resistant disease. This evidence concerns the gene HIF1A and breast neoplasm.